NCT06347068View on ClinicalTrials.gov

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2028

Conditions
Breast CancerRelapseResistant CancerTriple Negative Breast Cancer
Interventions
BIOLOGICAL

iC9-CAR.B7-H3 T Cell Therapy

iC9-CAR.B7-H3 T cells will then be administered intravenously

DRUG

cyclophosphamide

cyclophosphamide 300 mg/m2 IV will be given.

DRUG

fludarabine

fludarabine 30 mg/m2 IV will be given.

Trial Locations (1)

27599

RECRUITING

University of North Carolina, Chapel Hill

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

M.D. Anderson Cancer Center

OTHER

lead

UNC Lineberger Comprehensive Cancer Center

OTHER